Home > Rheumatology > EULAR 2022 > Treatment with bimekizumab beneficial in psoriatic arthritis

Treatment with bimekizumab beneficial in psoriatic arthritis

Presented By
Prof. Iain McInnes, Glasgow University, UK
EULAR 2022
The IL-17A/IL-17F blocker bimekizumab showed marked superiority in the primary and all ranked secondary endpoints of the phase 3 BE OPTIMAL trial as a therapy for psoriatic arthritis (PsA). At week 16, over 40% of study participants reached an ACR50 response. Prof. Iain McInnes (Glasgow University, UK) presented the late-breaking phase 3 results of the BE OPTIMAL study (NCT03895203) assessing bimekizumab in PsA patients who did never before receive biologics [1]. The trial enrolled 852 adult patients with at least 1 active PsA lesion and/or diagnosis of psoriasis. As may be expected in a trial for PsA, the baseline features of the cohort included a mean age around 49, under 50% men, and just under 60% on concomitant methotrexate. Also, about 50% of the participants had a body surface area affected by psoriasis of ≥3%. The 16-week double-blind phase consi...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on